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Abstract 
Extramedullary disease is relatively frequent in multiple myeloma, but our knowledge on the subject is 
limited and mainly relies on small case series or single center experiences. Little is known regarding the role 
of new drugs in this setting. We performed a meta-analysis of 8 trials focused on the description of 
extramedullary disease characteristics, clinical outcome, and response to new drugs. A total of 2332 newly 
diagnosed myeloma patients have been included, 267 (11.4%) had extramedullary disease, defined as 
paraosseous in 243 (10.4%), extramedullary plasmocytoma in 12 (0.5%), and not classified in 12 (0.5%) 
patients. Median progression-free survival was 25.3 months and 25.2 in extramedullary disease and non-
extramedullary disease patients, respectively.  In multivariate analysis the presence of extramedullary disease 
did not impact on progression-free survival (hazard ratio 1.15, p=0.06), while other known prognostic factors 
retained their significance. Patients treated with immunomodulatory drugs, mainly lenalidomide, or 
proteasome inhibitors had similar progression-free survival and progression-free survival-2 regardless of 
extramedullary disease presence. Median overall survival was 63.5 months and 79.9 months (p=0.01) in 
extramedullary and non-extramedullary disease patients, respectively, and in multivariate analysis the 
presence of extramedullary disease was associated with a reduced overall survival (hazard ratio 1.41, 
p<0.001), in line with other prognostic factors. With the limits of the use of low sensitivity imaging 
techniques, that lead to an underestimation of extramedullary disease, we conclude that in patients treated 
with new drugs the detrimental effect of extramedullary disease at diagnosis is limited, that lenalidomide is 
effective as are proteasome inhibitors, and that these patients tend to acquire a more aggressive disease in 
later stages. (EUDRACT2005-004714-32, NCT01063179. NCT00551928, NCT01091831, NCT01093196, 
NCT01190787, NCT01346787, NCT01857115). 
 
 
 
 
 
 
  
Introduction 
Multiple myeloma (MM) is a plasma cell neoplasia characterized by a diffuse tumor infiltration of the bone 
marrow, resulting, among others, in anemia, bone damage with hypercalcemia, and bone lesions. 
Occasionally,  neoplastic plasma cells acquire a different growth pattern generating tumor masses, that are 
referred to as extra-medullary disease (EMD).1 EMD can arise from skeletal focal lesions, which disrupt the 
cortical bone and grow as extra-bone masses, and is referred to as paraosseous plasmocytoma (PO), or derive 
from hematogenous spread as manifestation in soft tissues, and is called extramedullary plasmocytomas 
(EMP).  Incidence of EMD at diagnosis ranges between 6%-10%,2_4 while later in the course of the disease 
increases to 13%-26%,2,4 with a 32%-35% peak in case of relapse after allogeneic stem cell transplantation.5,6 
In the final stage of the disease an extraskeletal involvement is observed in approximately 70% of cases 
studied with autopsy,7 with a peculiar involvement of visceral sites.8 As expected, patients with EMD at 
diagnosis tend to maintain the same pattern at relapse.2  
The biological mechanisms behind the acquisition of the EMD-forming phenotype have not yet been fully 
elucidated. Increased expression of CXCR4 and CXCL12 plays a major role in promoting a bone marrow-
indipendent behavior, favoring dissemination and homing to distant and unusual sites.9,10 Other mechanisms 
are represented by reduced expression of several adhesion molecules, in particular VLA-4,  CD44, and 
CD56, and chemokine receptors, such as CCR1, and CCR2. Diversely, the cyclin D1 pathway seems to favor 
the bone marrow homing, protecting from extramedullary localizations, as t(11;14) is not observed in MM 
patients with EMD.11 
Despite its frequency and clinical relevance, EMD has been commonly neglected by the medical literature. 
In fact, almost all the available data derive from retrospective series and single center experiences, mainly 
reported  in the pre-new drug era, carrying the limitations of this type of studies. With the purpose to fill this 
gap and clarify the role of new drugs in MM with EMD, we conducted the largest  meta-analysis so far 
reported, based on 8 prospective trials by the same sponsors (Fonesa Onlus and Hovon Foundation)  
Methods 
Study design 
Patients with newly diagnosed MM enrolled in 8 clinical trials were retrospectively analyzed. Details on 
trials and treatment regimens are summarized in Table 1. Briefly, 3 trials enrolled transplant eligible, and 5 
trials transplant ineligible patients. Three trials included an immunomodulatory (IMiD) drug in the treatment, 
lenalidomide in almost all cases, 3 trials a proteasome inhibitor (PI), and 4 trials both. Six out of 8 trials 
included maintenance. Trials were approved by the Independent Ethics Committees/Institutional Review 
Boards at all participating centres. Patients provided written informed consent before entering the study, 
prepared in accordance with the Declaration of Helsinki. For the purpose of this meta-analysis, we 
considered the subgroup of patients with EMD, and compared them with patients without EMD.  
Extramedullary disease definition and assessment 
EMD was classified as PO disease, consisting of tumor masses arising directly from bones, or EMP, 
consisting of masses not contiguous to the bones and derived from hematogenous spread. EMD was 
identified at study enrollment with the diagnostic procedure required by the patient’s study protocol, such as 
x-ray skeletal survey, magnetic resonance imaging (MRI), computed tomography (CT), and physical 
examination. 
Statistical Analysis 
Differences in patient and disease characteristics for EMD patients versus non-EMD patients were 
investigated using Kruskal Wallis test for continuous variables and Fisher’s exact test for categorical 
variables. Data of trials were pooled together and analyzed. Time-to-event data were analyzed using the 
Kaplan–Meier method; EMD and non-EMD patients were compared with the log-rank test. The Cox 
proportional hazards models were used to estimate adjusted hazard ratios (HRs) and the 95% confidence 
intervals (CIs) for the main comparisons, EMD patients versus non-EMD patients. To account for potential 
confounders, the Cox models were adjusted for the age, sex, ISS stage ( I vs. II; I vs. III), cytogenetic risk 
defined by FISH analysis (high, i.e. presence of del(17p), t(4;14), t(14;16), vs. standard risk; missing vs. 
standard risk), and autologous stem cell transplantation (ASCT) (ASCT vs. non-ASCT; not applicable, i.e. 
patients not candidate to ASCT, vs. non-ASCT). Subgroup analyses were performed to determine the 
consistency of the overall effect in different subgroups using interaction terms for the comparison between 
EMD vs. non-EMD and each of the covariate included in the Cox model plus Revised ISS stage (RISS) and 
type of therapies (IMID and PI). All HRs were estimated with their 95% CI and two sided p-values. In order 
to evaluate the impact of different size and types of EMD, further subgroup analyses were performed: EMD 
size ≤ 3 vs. > 3 cm; EMD size ≤ 5 vs. > 5 cm; PO or EMP. Data were analyzed as of December, 2018 using 
and R (Version 3.1.1). 
Results 
Patients 
A total of 2332 patients were included in this analysis: 267 (11%) had EMD, while 2065 (89%) had no 
EMD. Median age of EMD patients was 68 years (IQ range 60-74), and 69 years (IQ range 61-74) in patients 
without EMD. International staging system was I in 119 (45%) and 682 (33%), II in 85 (32%) and 782 
(38%), and III in 38 (14%) and 509 (25%) patients with or without EMD, respectively. Clinical trials were 
based on IMiD in 166 (62%) and 1279 (62%) patients, on a PI in 66 (25%) and 464 (22%) patients, or both 
in 35 (13%) and 322 (16%) patients with or without EMD, respectively. Patient characteristics are 
summarized in Table 2. Patients with EMD had PO in 243 (91%), and an EMP in 12 (4%) cases, while the 
information was not available for other 12 (4%) patients. EMD localizations were single in 195 (73%), and 
multiple in 60 (22%) patients. Median EMD size was 4.2 cm (IQ range 3–7). EMD characteristics are 
summarized in Table 3. No differences were observed in patients with EMD ≤ or > 3 cm. EMD patients had 
a lower systemic tumor burden respect to patients without EMD, as shown by: plasma cell bone marrow 
infiltration 30% (IQ range 15% - 50%) vs. 50%  (IQ range 30% - 70%), hemoglobin 12.0 gr/L (IQ range 
10.5 – 13.6) vs. 10.7 gr/L (IQ range 9.5 – 12.1), median creatinine clearance 75 mL/min per 1.73 m2 (IQ 
range 48 – 98) vs 66 (IQ range 41 – 88), respectively. EMD patients had ISS I stage in 45% of cases, respect 
to 33% of non-EMD patients (p<0.001). 
Efficacy 
Progression-free survival 
The median follow-up was 62 months (IQ range 34-75) in EMD, and 65 months (IQ range 40-77) in non-
EMD patients. Median PFS was 25.3 months (95% CI 21.7 – 28.7) and 25.2 months (95% CI 24.2 – 27.0) in 
EMD and non-EMD patients, respectively. Five-year PFS was 19% (95% CI 15% – 25%) and 22% (95% CI 
20% – 24%) (p=0.46) in EMD and non-EMD patients, respectively (Figure S1), and there were no 
differences between EMP, PO, and non-EMD (Figure 1A). In multivariate analysis the presence of EMD did 
not impact on PFS (HR 1.15, 95% CI 0.99-1.33; p=0.06), while other known prognostic factors retained their 
significance: high risk vs. standard cytogenetic (HR 1.35, 95% CI 1.20 -1.52; p<0.001), and ISS III vs. I (HR 
1.74, 95% CI 1.53 -1.98; p<0.001) (Figure S4). Type of therapy had not impact on PFS: IMiD-based therapy 
(HR 1.14, 95% CI 0.96 – 1.35) and no IMiDs (HR 1.18, 95% CI 0.87 – 1.59)(interaction p = 0.86), PI-based 
therapy (HR 1.33, 95% CI 1.04 – 1.71) and no PI, (HR 1.04, 95% CI 0.87 – 1.25) (interaction p = 0.12), and 
ASCT in eligible patients (HR 1.10, 95% CI 0.81 – 1.50) and non-ASCT (HR 1.04, 95% CI 0.73 – 1.47) 
(interaction p = 0.72). A landmark analysis from maintenance start showed a median PFS of 23.4 months 
(95% CI 19.1 – 30.1) and 23.5 months (95% CI 21.8 – 25.7) (p=0.30) in EMD and non-EMD patients, 
respectively. EMD size was not correlated with median PFS: patients with EMD ≤3 cm 26.0 months (95% 
CI 18.5 – 37.1), patients with EMD >3 cm 23.7 months (95% CI 18.8 – 28.2), and patients without EMD 
25.2 months (95% CI 24.2 – 27.0) (Figure 2).  The same results were observed with the EMD size threshold 
at 5 cm (Figure S6). Median PFS according to EMD number was as follows: single EMD localization 26.1 
months (95% CI 22.5  – 30.1), multiple EMD localizations 19.4 months (95% CI 14.9  – 33.1), and no EMD 
25.2 months (95% CI 24.2  – 27.0). Median PFS was not correlated with EMD site: PO 24.3 months (95% CI 
21.2–28.2), EMP 26.1 months (95% CI 8.0  – NR), and no EMD 25.2 months (95% CI 24.2  – 27.0), PO vs. 
no EMD (HR 1.14, 95% CI 0.98-1.33; p=0.10), and EMP vs. no EMD (HR 1.23, 95% CI 0.64-2.37; 
p=0.54)(Figure 1A). Median PFS2 and 5-year PFS2 were 43.2 months (95% CI 37.0-52.4) and 38% (95% CI 
31% - 47%) in PO, 27.9 months (95% CI 4.9-NR) and NR in EMP, and 46.4 months (95% CI 44.1-48.9) and 
40% (95% CI 37% - 43%) in non-EMD patients (Figure 3).  
Overall survival 
Median OS was 63.5 months (95% CI 48.2 – 84.7) and 79.9 months (95% CI 75.8 – 88.3; p=0.01) in EMD 
and non-EMD patients, respectively. Five-year OS was 51% (95% CI 45% – 58%) and 59% (95% CI 57% – 
61%) (p=0.01) in EMD and non-EMD patients, respectively (Figure S3), and there was a significant 
difference between PO and non-EMD (HR 1.39, 95% CI 1.13-1.70; p=0.001) (Figure 1B). In multivariate 
analysis the presence of EMD was associated with a reduced OS (HR 1.41, 95% CI 1.16-1.71; p<0.001), in 
line with other known prognostic factors: high risk vs. standard cytogenetic (HR 1.68, 95% CI 1.44 -1.96; 
p<0.001), ISS III vs. I (HR 2.36, 95% CI 1.98 -2.82; p<0.001) (Figure S5). Type of therapy did not impact 
on OS: IMiD-based therapy (HR 1.38, 95% CI 1.10 – 1.73) and no IMiDs (HR 1.47, 95% CI 1.01 – 2.13) 
(interaction p = 0.78), PI-based therapy (HR 1.43, 95% CI 1.04 – 1.97) and no PI, (HR 1.39, 95% CI 1.09 – 
1.76) (interaction p = 0.87), and ASCT in eligible patients (HR 1.45, 95% CI 0.95 – 2.20) and non-ASCT 
(HR 1.40, 95% CI 0.88 – 2.25) (interaction p = 0.99). A landmark analysis by maintenance start showed a 
median OS of 69.1 months (95% CI 64.6 – NR) and 87.8 months (95% CI 87.8 – NR) (p=0.22) in EMD and 
non-EMD patients, respectively. EMD size was not correlated with median OS: patients with EMD ≤3 cm 
58.5 months (95% CI 38.4 – NR), patients with EMD >3 cm 63.7 months (95% CI 48.2 – NR), and patients 
without EMD 79.9 months (95% CI 75.8 – 88.3) (Figure 4). The same analysis was done with the EMD size 
threshold at 5 cm (Figure S7). Median OS according to EMD number was as follows: single EMD 
localization 70.1 months (95% CI 50.4  – NR), multiple EMD localizations 45 months (95% CI 38.2  – NR), 
and no EMD 79.9 months (95% CI 75.8  – 88.3), single EMD vs. no EMD (HR 1.33, 95% CI 1.07-1.67; 
p=0.01), and multiple EMD localizations vs. no EMD (HR 1.62, 95% CI 1.11-2.38; p=0.01). Median OS was 
not correlated with EMD site: PO 67.3 months (95% CI 50.4  – NR), EMP 70.1 months (95% CI 16.9  – 
NR), and no EMD 79.9 months (95% CI 75.8  – 88.3), PO vs. no EMD (HR 1.39, 95% CI 1.13-1.70; 
p=0.001), and EMP vs. no EMD (HR 1.24, 95% CI 0.55-2.78; p=0.60) (Figure 1).  
Discussion 
To the best of our knowledge, this is the first meta-analysis of MM clinical trials focusing on patients with 
EMD so far reported. We included 8 Fonesa Onlus and Hovon Foundation clinical trials that enrolled 2332 
newly diagnosed patients. In this population, we observed 267 (11%) patients with one or more EMD 
localizations, including 243 PO, 12 EMP, and 12 cases that were not classified. Since none of the clinical 
trial considered in this study had as primary endpoint the study of EMD, and a proportion of them were 
started around 10 years ago, the most common imaging procedure performed at enrollment as screening was 
x-ray skeletal survey, and, only in case of a suspect of EMD, MRI or CT scan. X-ray skeletal survey is 
clearly suboptimal in detecting extramedullary asymptomatic disease. Nevertheless, the EMD incidence we 
observed is in line with other case series (in the range of 7%-18%),1 suggesting that our patient population is 
quite representative of the daily clinical practice. Anyway, it is expected that a wider use of more sensitive 
imaging techniques, such as positron emission tomography (PET), whole-body CT, and MRI will increase 
EMD detection.12,13  Interestingly, we observed that EMD patients had less disease burden, as shown by a 
more favorable ISS, lower bone marrow plasma cell infiltrate, higher hemoglobin levels, and a better renal 
function. This finding has been observed also by others in the first line setting,2,14 and may reflect a specific 
clinical picture, characterized by symptoms attributable to the EMD, rather than to larger disease burden. 
The presence of EMD at diagnosis did not impair the first line PFS, since EMD patients had a median PFS of 
25.3 months, similar to the 25.2 months observed in patients without EMD. This finding is quite remarkable, 
since presence of EMD has long been recognized as an unfavorable  prognostic factor, both in case of PO 
and EMP.4 Varettoni et al. described 76 EMD patients out of 1003 MM patients at diagnosis, and with a 
treatment based on conventional chemotherapy the PFS of EMD was 18 vs. the 30 months of patients 
without EMD (p=0.03).2 Only EMD patients who received an ASCT had a PFS  similar to that of patients 
without EMD. Likewise, Wu et al. described 75 EMD patients at diagnosis, who were compared to 384 cases 
without EMD, and observed that EMD patients had an inferior PFS respect to that of patients without EMD, 
but this difference was overcome when EMD patients received ASCT.14 Hence, the presence of EMD at 
diagnosis has been incorporated as an adverse component of the Durie and Salmon PLUS prognostic score.15 
Since we did not observe any significant difference in PFS between EMD and non-EMD patients, it is 
reasonable to speculate that the incorporation of new drugs in all the regimens tested in the studies included 
in this meta-analysis was able to overcome the unfavorable prognostic significance of EMD. In this 
perspective, several case reports, as well as few trials, have shown that new drugs are effective in MM 
patients with EMD. In particular, Landau et al. have evaluated in 42 high risk MM at diagnosis, including 14 
patients with EMD, an induction with 3 cycles of bortezomib, liposomal doxorubicin and dexamethasone, 
followed by ASCT, with an acceptable median  time-to-progression of  39 months.16 In our meta-analysis 
166 EMD patients were treated with IMiD-based therapies, almost lenalidomide in all cases, and have been 
compared with 1279 no EMD patients that have received the same treatment. Quite surprisingly, also in this 
subset the PFS was not different between the two groups, suggesting that lenalidomide can be active also in 
this setting, as suggested by very few case reports.17 This is in contrast with the observation derived from 
studies involving thalidomide, the first-in-class IMiD, which resulted in having no effect on EMD,18 and this 
may be accounted to the higher direct cytotoxic effect of lenalidomide respect to thalidomide.19 Interestingly, 
in our study EMD patients treated with IMiDs had the same PFS and OS of patients treated with PIs (Figure 
S8). 
Previous studies shown that increasing the therapy intensity, i.e. intensifying the treatment with ASCT, 
overcame the negative prognostic significance of EMD presence.20 This has been confirmed in a large 
European Bone Marrow Transplantation registry study that considered 3744 MM patients, including 353 
with EMD, who received ASCT at diagnosis.  This study has shown how patients with a single EMD had a 
similar PFS respect to patients without EMD.21 Since intensification seems to be the key to EMD control, it 
is possible to speculate that new drugs may offer an adequate level of treatment intensity, respect to 
conventional drugs. In the pre-new drug era, this goal was obtained only with ASCT.  In order to evaluate 
whether the high efficacy of new drugs results into a more aggressive relapse, we analyzed PFS2, and we 
observed that EMD patients benefited from a similar disease control when compared to patients without 
EMD (42.3 vs. 46.4 months, respectively). This suggests that patients retain the benefit beyond the first line.  
Interestingly, also maintenance seems to have a similar efficacy in EMD and non-EMD patients. Median OS 
of EMD patients was inferior when compared with the control group (63.5 vs. 79.9 months, respectively), 
and this is irrespective of the type of therapy. Since PFS2 is similar between the 2 groups, it is safe to suggest 
that MM with EMD may acquire a more aggressive behavior in later stages of the disease.  
Doubtless, the most sensitive technique for plasmacytoma identification is PET, which is able to upgrade 
myeloma-related lesion identification in more than half of patients when compared with X-ray skeletal 
survey.22 Unfortunately, in our study PET was not used, since, at the time the trials were performed, this 
technique was not standard. The recent IMAJEM trial, by the Intergroupe Francophone du Myelome (IFM), 
has shown that spine and pelvis MRI and PET are positive in 95% and 91% of patients at diagnosis, 
respectively, and that PET has a strong prognostic significance in terms of PFS and OS when evaluated both 
after the induction phase, represented by three cycles of lenalidomide plus bortezomib plus dexamethasone, 
and before maintenance start.23 Moreover, the IFM trial has shown that patients with EMD, evaluated with 
PET at diagnosis, have an increased risk of EMP relapse, progression or death (HR 3.4, 95% CI 2.1-5.6, 
p<0.01). These data reinforce the concept that EMP has a strong detrimental effect on survival, but a specific 
analysis on the clinical significance of PO disease was not provided.   
Surprisingly, we did not find any significant correlation between outcome and EMD size. A similar finding 
has been reported in the setting of solitary EMD. Eighty-four patients have been evaluated and no differences 
in terms of outcome have been seen between patients with EMD ≤5 cm, >5 and ≤10 cm, and >10 cm.24 
Probably, the presence of a EMD is detrimental for the relevant biological features that are inherent in this 
variant of plasma cell neoplasm, rather than EMD size.25 Also the presence of single or multiple EMD 
localizations was not prognostically significant. Unfortunatly, in our study EMD was mainly represented by 
PO disease, since many EMPs were probably missed due to the imaging techniques used at time of trial 
design. Our observations are in contrast with the study by Rasche et al.,26 who evaluated with diffusion-
weighted MRI 404 transplant-eligible patients and showed that the presence of 3 or more large focal lesions, 
defined as lesions with a product of the perpendicular diameters >5 cm2, were strong independent adverse 
prognostic factors. A possible explanation for this inconsistency can be attributed to the fact that Rasche et 
al. have considered all types of focal lesions, including intraosseous focal lesions, while in our study we have 
analyzed only EMD. Finally, we did not observe any significant correlation between EMP and outcome, but 
this is probably due to the limited number of cases observed in this study.  
In conclusion, the main limit that our study suffered is represented by an underestimation of EMD and, in 
particular, EMP incidence, caused by the low resolution of  the imaging techniques employed at screening. 
Thus, our findings can be mainly referable to PO localizations, which are known to be less aggressive than 
EMP,27 and this limits the value of our results. On the other hand, we performed the largest analysis of EMD 
patients at diagnosis, with the strength of using solid data derived from prospective trials. We confirmed that 
PIs are effective towards EMD, and, for the first time, we provide evidence that also lenalidomide is 
effective in this difficult setting. We hope that our and other similar studies will encourage focusing the 
attention on this unmet clinical need with trials specifically designed for MM patients with EMD.  
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Trial Code Treatment Drugs Maintenance N. of  Patients 
Years 
Enrollement 
Age 
population 
Outcome 
PFS 
Outcome 
OS 
Pubblication 
Year(s) 
GIMEMA-MM-05-0528  2005-004714-32 
4 PAD induction followed by 2 
Mel100 intensification followed 
by 4 RP consolidation and R 
maintenance 
IMiD-PI yes 103 2005-2008 ≤75 
Median PFS: 
48 months 
 
5yrs OS: 
63% 
2010-2013 
GIMEMA-MM-03-0529  NCT01063179 
9 VMP induction or 9 VMPT 
induction followed by 2 years 
VT maintenance 
IMiD-PI Random for FDT 
or observation 511 2006-2009 ≥65 
Median PFS: 
VMPT-VT: 35 months 
VMP: 25 months 
5yrs OS: 
VMPT-VT: 61% 
VMP:51% 
2010-2014 
RV-MM-PI-20930 NCT00551928 
4 Rd induction, mobilization, 6 
MPR or 2 Mel200 intensification 
followed by R maintenance until 
PD or observation 
PI 
Random for 
maintenance  or 
observation 
402 2007-2009 <65 
Median PFS: 
MPR: 22 months 
ASCT: 43 months 
4yrs OS: 
MPR: 65% 
ASCT: 81% 
2014 
RV-MM-EMN-44131 NCT01091831 
4 Rd induction, mobilization, 6 
CPR or 2 Mel200 intensification 
followed by RP or R 
maintenance until PD 
IMiD yes 389 2009-2011 <65 
Median PFS: 
CRD: 29 months 
ASCT: 43 months 
4yrs OS: 
CRD: 73% 
ASCT: 86% 
2015 
EMN0132 NCT01093196 
9 Rd or MPR or CPR induction 
followed by RP or R 
maintenance until PD  
IMiD yes 654 2009-2012 ≥65 
Median PFS: 
MPR: 24 months 
CPR: 20 months 
Rd: 21 months 
4yrs OS: 
MPR: 65% 
CPR: 68% 
Rd: 58% 
2016 
MMY206933 NCT01190787 
9 VP or CVP or VMP induction 
followed by V maintenance until 
PD 
PI yes 152 2010-2012 ≥65 
Median PFS: 
VP: 14 months 
VCP: 15 months 
VMP: 17 months 
 
2yrs OS: 
VP: 60% 
VCP: 70% 
VMP: 76% 
2016 
IST-CAR-50634 NCT01346787 9 KCd induction followed by K 
maintenance until PD PI yes 58 2011-2012 ≥65 
2yrs PFS: 76%, 
 
2yrs OS: 87% 2014 
IST-CAR-56135 NCT01857115 9 KCd induction followed by K 
maintenance until PD PI yes 63 2013-2015 ≥65 
2yrs PFS: 53%,  
 
2yrs OS: 81% 2018 
Table 1. Source Studies. V, Bortezomib; M, Melphalan; P, Prednisone; T, Thalidomide; C, Cyclophosphamide; K, Carfilzomib; R, Lenalidomide; d, 
Dexamethasone; Mel200, High dose Melphalan; PAD, Bortezomib-pegylated liposomal doxorubicin- Dexamethasone; PD, Progression Disease; IMiD, 
Immunomodulatory drug ; PI, Proteasome inhibitor ; PFS, Progression-free Survival; OS, Overall Survival, FDT, Fixed-duration Therapy.  
Characteristic Patients with extra-
medullary disease 
(N=267) 
Control group 
(N=2065) 
p-
value 
Age 
   Median (IQR)-yr 
   Distribution – no. (%) 
   <65 yr 
   65 to 75 
   ≥ 75 
 
68 (60-74) 
 
108 (40%) 
105 (39%) 
54 (21%) 
 
69 (61-74) 
 
477 (38%) 
795 (38%) 
493 (24%) 
0.21 
ECOG 
   0 
   1 
   2 
   3  
 
107 (40%) 
103 (39%) 
39 (15%) 
1 (0%) 
 
847 (41%) 
862 (42%) 
235 (11%) 
7 (0%) 
0.35 
ISS 
   I 
   II 
   III 
   missing 
 
119 (45%) 
85 (32%) 
38 (14%) 
25 (9%) 
 
682 (33%) 
782 (38%) 
509 (25%) 
92 (4%) 
<0.001 
R-ISS 
   I 
   II 
   III 
   missing 
 
38 (14%) 
125 (47%) 
17 (6%) 
87 (33%) 
 
294 (14%) 
1132 (55%) 
173 (8%) 
466 (23%) 
0.62 
FISH – no. (%) 
   Standard risk 
   High risk* 
       del(17p) 
       t(4;14) 
       t(14;16) 
   Missing 
 
115 (43%) 
51 (19%) 
32  
22  
6 
101 (38%) 
 
1082 (52%) 
446 (22%) 
220  
219  
69  
537 (26%) 
0.72 
LDH – IU/L 
   ≤450 201  
   >450 201 
   missing 
 
201 (75%) 
29 (11%) 
37 (14%) 
 
1567 (76%) 
180 (9%) 
318 (15%) 
0.30 
Bone marrow plasma cells, median (IQR)    30% (15% - 50%) 50% (30% - 70%) <0.001 
Hemoglobin, median (IQR) – gr/L 12.0 (10.5 – 13.6) 10.7 (9.5 – 12.1) <0.001 
Creatinine clearance 
   Median (IQR) – mL/min per 1.73/m2 
   < 30 mL/min per 1.73/m2 
   30 to 60 mL/min per 1.73/m2 
   > 60 mL/min per 1.73/m2 
 
75 (48-98) 
45 (17%) 
49 (18%) 
172 (64%) 
 
66 (41-88) 
359 (17%) 
544 (26%) 
1162 (56%) 
0.01 
Therapy 
   IMiD-based 
   PI-based 
   IMiD + PI-based 
 
166 (62%) 
66 (25%) 
35 (13%) 
 
1279 (62%) 
464 (22%) 
322 (16%) 
0.48 
Autologous stem cell transplantation 155 (58%) 1283 (62%) 0.17 
Fixed-duration therapy  
Continuous treatment 
No Maintenance 
31 (12%) 
128 (48%) 
108 (40%) 
243 (12%) 
1007 (49%) 
815 (39%) 
1.00 
Imaging technique     
   X-ray skeletal survey 
   CT-scan 
   MRI 
   Physical examination 
   Spiral CT 
   Conventional CT 
   Unknown 
0 (0 %) 
0 (0 %) 
115 (43 %) 
21 (8 %) 
13 (5%) 
96 (36%) 
22 (8%) 
989 (42%) 
  122 (6 %) 
277 (13 %) 
0 (0 %) 
0 (0%) 
2 (0%) 
675 (33%) 
<0.001 
 
Table 2. Patients’ demographics and clinical characteristics. *More than one FISH abnormality may 
occur in the same patient. NS, not significant; NA, not assessable; IQR, interquartile range; IMiD, 
immunomodulatory drug; PI, proteasome inhibitor; CT, computed tomography; MRI, magnetic resonance 
imaging.  
 
Characteristic No. patients   267 
Size, median (IQR)-cm 4.2 (3-7) 
Para-skeletal  
Extramedullary plasmocytoma 
Not classifiable 
243 (91%) 
12 (4.5%) 
12 (4.5%) 
Single 
Multiple 
Not classifiable 
195 (73%) 
60 (22%) 
12 (5%) 
Involvement sites*§ 
   Pelvis 
   Skull 
   Spine 
   Thorax (excluded dorsal spine) 
   Long bones 
   Not classifiable 
 
38 
10 
117 
67 
14 
34 
Table 3. Extramedullary disease characteristics. *Sites of extramedullary disease (EMD) localizations 
were not available. § The sum of the sites is greater than the total number of EMD patients, since one patient 
could present with more than one localization.  
  
FIGURE TITLES AND LEGENDS 
 
Figure 1. PFS and OS according to extramedullary disease presence and type. Panel A, PFS; panel B, 
OS. 
EMD, extramedullary disease; EMP extramedullary plasmocytoma; PO, paraosseous plasmocytoma. 
Figure 2. PFS according to extramedullary disease features.  Panel A, PFS according to extramedullary 
disease (EMD) presence and size; panel B, PFS according to single or multiple EMD localizations. 
EMD, extramedullary disease. 
Figure 3. PFS2. 
EMD, extramedullary disease; EMP extramedullary plasmocytoma; PO, paraosseous plasmocytoma. 
Figure 4. OS according to extramedullary disease features.   Panel A, OS according to EMD presence 
and size; panel B, OS according to single o multiple EMD. 
EMD, extramedullary disease. 
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Endpoints 
Overall survival (OS) was calculated from date of study entry to the date of death for any cause or the date 
the patient was last known to be alive. Progression-free survival (PFS) was calculated from date of study 
entry to the date of second progression or death for any cause, whichever comes first, or the date the patient 
was last known to be in remission. Progression-free survival (PFS) was calculated from date of study entry to 
the date of progression or death for any cause, whichever comes first, or the date the patient was last known 
to be in remission. 
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Figure S1: PFS according to extramedullary disease presence and type 
 
EMD, extramedullary disease.  
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Figure S2: PFS2 according to extramedullary disease presence and type 
 
EMD, extramedullary disease.  
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Figure S3: OS according to extramedullary disease presence and type 
 
EMD, extramedullary disease.  
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Figure S4: Subgroup  analysis for PFS in the intent-to-treat population for extramedullary versus non- 
extramedullary 
 
EMD, extramedullary disease.  
  
0.73 2.16
1.15 (0.99 - 1.33)Overall
age
<60 1.08 (0.80 - 1.46) 0.97
60-69 1.17 (0.81 - 1.68)
70-74 1.19 (0.94 - 1.50)
75 1.14 (0.84 - 1.56)
sex
F 1.27 (1.02 - 1.58) 0.24
M 1.07 (0.87 - 1.30)
Citogenetic Risk
Standard 1.10 (0.88 - 1.36) 0.69
High 1.30 (0.94 - 1.78)
Missing 1.14 (0.89 - 1.47)
ISS
I 1.13 (0.89 - 1.43) 0.75
II 1.07 (0.83 - 1.37)
III 1.32 (0.93 - 1.88)
Missing 1.30 (0.78 - 2.16)
RISS
I 1.45 (0.99 - 2.12) 0.43
II 1.05 (0.85 - 1.29)
III 1.28 (0.77 - 2.12)
Missing 1.03 (0.78 - 1.37)
IMID
No 1.18 (0.87 - 1.59) 0.86
Yes 1.14 (0.96 - 1.35)
PI
No 1.04 (0.87 - 1.25) 0.12
Yes 1.33 (1.04 - 1.71)
ASCT
No 1.04 (0.73 - 1.47) 0.72
Yes 1.10 (0.81 - 1.50)
Not Applicable 1.20 (1.00 - 1.45)
HR (95% CI) Interaction-p
Favors EMD Favors no-EMD
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Figure S5: Subgroup  analysis for OS in the intent-to-treat population for extramedullary versus non- 
extramedullary 
 
EMD, extramedullary disease.  
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age
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High 1.47 (1.02 - 2.14)
Missing 1.30 (0.91 - 1.84)
ISS
I 1.48 (1.05 - 2.08) 0.22
II 1.43 (1.05 - 1.95)
III 1.04 (0.66 - 1.62)
Missing 2.29 (1.25 - 4.19)
RISS
I 1.58 (0.87 - 2.86) 0.84
II 1.40 (1.08 - 1.81)
III 1.12 (0.63 - 1.99)
Missing 1.26 (0.86 - 1.85)
IMID
No 1.47 (1.01 - 2.13) 0.78
Yes 1.38 (1.10 - 1.73)
PI
No 1.39 (1.09 - 1.76) 0.87
Yes 1.43 (1.04 - 1.97)
ASCT
No 1.40 (0.88 - 2.25) 0.99
Yes 1.45 (0.95 - 2.20)
Not Applicable 1.40 (1.10 - 1.77)
HR (95% CI) Interaction-p
Favors EMD Favors no-EMD
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Figure S6: PFS according to extramedullary disease ≤ or > 5 cm 
 
EMD, extramedullary disease.  
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Figure S7: OS  according to extramedullary disease ≤ or > 5 cm 
 
EMD, extramedullary disease.  
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Figure S8: OS  according to extramedullary disease presence and type of therapy 
 
EMD, extramedullary disease; IMiD, immunomodulatory drug; PI, proteasome inhibitor.  
  
11 
 
FISH testing 
Fluorescence in situ hybridization analyses were performed on bone marrow plasma cells purified with anti-
CD138–coated magnetic beads as previously described.1  Deletion of chromosome 13 (del13) was analyzed 
with an locus-specific identifier (LSI) 13 DNA probe; chromosome 17 deletion (del17) was detected with an 
LSI 17p13.1 probe combined with 17 α-satellite DNA centromere probe. LSI immunoglobulin H 
(IgH)/fibroblast growth factor receptor 3 dual fusion translocation probe (FGFR3, 4p16) was used for the 
detection of IgH/FGF3 fusion resulting from t(4;14)(p16;q32); LSI IgH/cyclin D1 (CCND1, 11q13) was 
used to detect IGH/CCND1 fusion resulting from t(11;14)(q13;q32), and LSI IgH/c-maf (MAF, 16q23) was 
used for the detection of the IgH/MAF fusion resulting from t(14;16)(q32;q23). 
 
1. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, 
Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-
Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004 Feb 
15;64(4):1546-58. 
 
